PLGA nanoparticles co-delivering BCL2 and MDR1 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer - Chitra Risnayanti; Ahn Hyung Jun
Keywords: siRNA; Chemoresistance; PLGA nanoparticles; ovarian cancer; chemotherapy; combination therapy